Clinical trials
Observational Necrosis trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
20 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 1 |
| 2009 | 1 |
| 2010 | 2 |
| 2011 | 1 |
| 2013 | 2 |
| 2015 | 3 |
| 2017 | 1 |
| 2019 | 2 |
| 2020 | 2 |
| 2023 | 2 |
| 2025 | 1 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 8 |
| Unknown status | 7 |
| Active, not recruiting | 2 |
| Not yet recruiting | 2 |
| Withdrawn | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Ole Hyldegaard | 2 |
| Baxter Healthcare Corporation | 1 |
| Collegium Medicum w Bydgoszczy | 1 |
| Hospital Clinic of Barcelona | 1 |
| Libin Cardiovascular Institute of Alberta | 1 |
| Mathys Ltd Bettlach | 1 |
| Mayo Clinic | 1 |
| Methodist Health System | 1 |
| NYU Langone Health | 1 |
| Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Necrosis | 20 |
| Cardiovascular Diseases | 4 |
| Heart Diseases | 4 |
| Infections | 4 |
| Myocardial Infarction | 4 |
| Vascular Diseases | 4 |
| Breast Neoplasms | 3 |
| Infarction | 3 |
| Myocardial Ischemia | 3 |
| Wounds and Injuries | 3 |
Trials
Showing 51 to 20 of 20. Each trial links to its page on Pharma Observatory.
No trials match these filters.
Try a different keyword, or clear a filter.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.